The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia

• Status: Completed
• Trial end date: 2016-12-11
• Target enrollment: 0
• Participant gender: All

Summary

Background: Patient with stage 3 or 4 chronic kidney disease (CKD) usually has normal level of serum phosphate, due to increased serum fibroblast growth factor-23 (FGF23) level that resulted in increased phosphate urine excretion. On the other hand, serum FGF23 elevation was related to CKD progression, vascular calcification, cardiomegaly, and mortality. This double blind, randomized controlled trial study was conducted to evaluate effectiveness and safety of calcium carbonate administration in stage 3 or 4 CKD patients with normophosphatemia.

Hypothesis: Calcium carbonate administration is effective and safe in chronic kidney disease (CKD) with normophosphatemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University
• Collaborator: Dr Cipto Mangunkusumo General Hospital
• Treatments: Calcium; Calcium Carbonate; Calcium, Dietary

Criteria

Inclusion Criteria:

• Stage 3 or 4 chronic kidney disease patient that visit nephrology or endocrinology outpatient clinic of dr. Cipto Mangunkusumo Hospital

• Normal level of serum phosphate

• Agreed to join in this study

Exclusion Criteria:

• Subjects with BMI < 18.5 kg/m2 or > 30 kg/m2

• Consume drugs which may interfere bone mineral metabolism